Analysts at Royal Bank of Canada assumed coverage on shares of Dyne Therapeutics (NASDAQ:DYN – Get Free Report) in a report ...

Analyst Michael Ulz from Morgan Stanley reiterated a Buy rating on Dyne Therapeutics (DYN – Research Report) and keeping the price target ...

Dyne Therapeutics, Inc. (NASDAQ:DYN – Get Free Report) has been given a consensus rating of “Buy” by the ten ratings firms ...